A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia
Primary result · CV death, recurrent MI, repeat revascularizationResult — go to the resultHazard ratio 0.24 95% CI 0.02–2.16Authors' conclusion
In this exploratory study including patients with ACS and CAE of the culprit artery, the use of rivaroxaban 15mg in addition to clopidogrel was not associated with a statistically lower risk of major adverse cardiovascular events; however, a lower rate of recurrent MI and a reduction in fibrin clot lysis time were observed.
Study context
- Population
- Patients with acute coronary syndrome (ACS) and coronary artery ectasia of the culprit infarct artery
- Participants
- 62 patients
- Comparison
- Single antiplatelet (SAPT)+DOAC vs dual antiplatelet therapy (DAPT)
- SAPT+DOACn = 30
- DAPTn = 32reference
- Primary endpoint
- Composite of CV death, recurrent MI and repeat revascularization; total bleeding events (BARC 1-5)
- Follow-up
- 12 months
Methodological detailsopen label, exploratory
- Open label
- Exploratory
Primary result
CV death, recurrent MI, repeat revascularization
Hazard ratio
0.24
95% CI 0.02–2.16
P = 0.20
SAPT+DOACvs DAPT
HR 0.24 (95% CI 0.02–2.16); P = 0.20
As reported in the abstract
Secondary outcomes
Recurrent MI · numerically lower rate with SAPT+DOAC
| Outcome | DAPT | SAPT+DOAC |
|---|---|---|
| Fibrin clot lysis time (turbidimetry)Reduction | −14.7% | −24.7% |
| P | P = .25 | P = .038 |
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Total bleeding events (BARC 1-5) (co-primary) · 12 monthsNot different | 0.75 (0.26–2.16) | P = 0.59 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia. Am Heart J. Published 29 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →